FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|June 28, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 28, 2022
Author(s)Sydney Jennings
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the Centers for Disease Control and Prevention (CDC) as of today, June 28, 2022, at 3:38 PM, EDT:
47.2% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.
What percentage of people across age groups in the US have been fully vaccinated?
• 66.8% of total US population
• 71% of US population aged ≥5 years
• 75.3% of US population aged ≥12 years
• 76.8% of US population aged ≥18 years
• 91.3% of US population aged ≥65 years
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, June 28, 2022 at 6:20 PM, EDT, there have been:
• 87 217 670 confirmed cases and
• 1 016 735 deaths
• 591 332 073 total vaccine doses administered
• 1 016 735 deaths
• 591 332 073 total vaccine doses administered
In the past 28 days, the 3 states with the most new cases are:
1. California: 426 952
2. Florida: 321 985
3. Texas: 227 645
2. Florida: 321 985
3. Texas: 227 645
Deaths: California has the highest number of deaths due to COVID-19 with 92 206 reported fatalities, followed by Texas with 88 660 and Florida with 75 671.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 545 252 291 confirmed cases, 6 332 325 deaths, and 11 697 294 922 vaccine doses administered.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Advertisement
Advertisement
Trending on Patient Care Online
1
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
2
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
3
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5